ESR1 and breast carcinoma: XBP1 was analyzed using C-map, which suggested the presence of 202 drugs that inhibit XBP1 expression (score:|>90|) with a similar effect as knockdown of the gene, which could reduce the risk of AF and breast cancer (total, ER+) (Supplementary Table S16).